243 related articles for article (PubMed ID: 3916624)
1. Long-term application of wearable artificial endocrine pancreas--closed-loop intravenous vs subcutaneous insulin infusion.
Shichiri M; Kawamori R; Goriya Y; Yamasaki Y; Nomura M; Asakawa N; Kubota M; Kamada T
Life Support Syst; 1985; 3 Suppl 1():583-7. PubMed ID: 3916624
[TBL] [Abstract][Full Text] [Related]
2. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas.
Shimoda S; Nishida K; Sakakida M; Konno Y; Ichinose K; Uehara M; Nowak T; Shichiri M
Front Med Biol Eng; 1997; 8(3):197-211. PubMed ID: 9444512
[TBL] [Abstract][Full Text] [Related]
3. Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas.
Matsuo Y; Shimoda S; Sakakida M; Nishida K; Sekigami T; Ichimori S; Ichinose K; Shichiri M; Araki E
J Artif Organs; 2003; 6(1):55-63. PubMed ID: 14598126
[TBL] [Abstract][Full Text] [Related]
4. Validation of closed-loop subcutaneous insulin infusion algorithm--application of subcutaneous insulin absorption kinetics.
Asakawa N; Saito Y; Yamasaki Y; Kawamori R; Shichiri M
Diabetes Res; 1987 Aug; 5(4):193-8. PubMed ID: 3311559
[TBL] [Abstract][Full Text] [Related]
5. The development of wearable-type artificial endocrine pancreas and its usefulness in glycaemic control of human diabetes mellitus.
Shichiri M; Kawamori R; Hakui N; Asakawa N; Yamasaki Y; Abe H
Biomed Biochim Acta; 1984; 43(5):561-8. PubMed ID: 6477542
[TBL] [Abstract][Full Text] [Related]
6. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas.
Weinzimer SA; Steil GM; Swan KL; Dziura J; Kurtz N; Tamborlane WV
Diabetes Care; 2008 May; 31(5):934-9. PubMed ID: 18252903
[TBL] [Abstract][Full Text] [Related]
7. Comparison between closed-loop portal and peripheral venous insulin delivery systems for an artificial endocrine pancreas.
Sekigami T; Shimoda S; Nishida K; Matsuo Y; Ichimori S; Ichinose K; Shichiri M; Sakakida M; Araki E
J Artif Organs; 2004; 7(2):91-100. PubMed ID: 15309676
[TBL] [Abstract][Full Text] [Related]
8. The development of artificial endocrine pancreas. From bedside-, wearable-type to implantable one.
Shichiri M; Kawamori R; Yamasaki Y
Med Prog Technol; 1987; 12(1-2):39-50. PubMed ID: 3627019
[TBL] [Abstract][Full Text] [Related]
9. Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy.
Rizza RA; Gerich JE; Haymond MW; Westland RE; Hall LD; Clemens AH; Service FJ
N Engl J Med; 1980 Dec; 303(23):1313-8. PubMed ID: 7001229
[TBL] [Abstract][Full Text] [Related]
10. On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with Type 1 diabetes.
Schaller HC; Schaupp L; Bodenlenz M; Wilinska ME; Chassin LJ; Wach P; Vering T; Hovorka R; Pieber TR
Diabet Med; 2006 Jan; 23(1):90-3. PubMed ID: 16409572
[TBL] [Abstract][Full Text] [Related]
11. Fuzzy-based controller for glucose regulation in type-1 diabetic patients by subcutaneous route.
Campos-Delgado DU; Hernández-Ordoñez M; Femat R; Gordillo-Moscoso A
IEEE Trans Biomed Eng; 2006 Nov; 53(11):2201-10. PubMed ID: 17073325
[TBL] [Abstract][Full Text] [Related]
12. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
13. An artificial endocrine pancreas--problems awaiting solution for long-term clinical applications of a glucose sensor.
Shichiri M; Fukushima H; Sakakida M; Kajiwara K; Hashiguchi Y
Front Med Biol Eng; 1991; 3(4):283-92. PubMed ID: 1799562
[TBL] [Abstract][Full Text] [Related]
14. [Long-term clinical application of wearable artificial endocrine pancreas].
Konno Y; Nishida K; Shimoda S; Sakakida M; Shichiri M
Nihon Rinsho; 1997 Nov; 55 Suppl():282-7. PubMed ID: 9434481
[No Abstract] [Full Text] [Related]
15. Continuous intravenous insulin therapy with a miniaturized open-loop system.
Renner R; Hepp KD; Mehnert H; Franetzki M
Horm Metab Res Suppl; 1979; (8):186-90. PubMed ID: 395077
[TBL] [Abstract][Full Text] [Related]
16. Closed-loop glycemic control with a wearable artificial endocrine pancreas. Variations in daily insulin requirements to glycemic response.
Shichiri M; Kawamori R; Hakui N; Yamasaki Y; Abe H
Diabetes; 1984 Dec; 33(12):1200-2. PubMed ID: 6389235
[TBL] [Abstract][Full Text] [Related]
17. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of automating insulin delivery for the treatment of type 1 diabetes.
Steil GM; Rebrin K; Darwin C; Hariri F; Saad MF
Diabetes; 2006 Dec; 55(12):3344-50. PubMed ID: 17130478
[TBL] [Abstract][Full Text] [Related]
19. [From external to implantable insulin pump, can we close the loop?].
Renard E; Costalat G; Bringer J
Diabetes Metab; 2002 Sep; 28(4 Pt 2):2S19-2S25. PubMed ID: 12442060
[TBL] [Abstract][Full Text] [Related]
20. Not the artificial beta cell algorithms but their parameter values are important in automated glucose control of insulin-dependent diabetes.
Fischer U; Jutzi E; Albrecht G; Abel P; Salzsieder E; Freyse EJ; Detscheff W; Lemke K
Trans Am Soc Artif Intern Organs; 1983; 29():488-91. PubMed ID: 6673274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
